长期肉毒神经毒素治疗后中和抗体高患病率
这项单中心观察性横断面研究纳入596例因不同神经科适应证接受A型肉毒神经毒素(BoNT/A)治疗的门诊患者,用ELISA检测结合抗体、阳性样本经小鼠半膈肌试验检测中和抗体(NAbs)。83例(13.9%)可测出NAbs;发生NAbs的概率随单次剂量和累积剂量增加而升高,并受BoNT/A制剂影响,疾病种类与治疗时长无额外影响。
要点
- 596例长期接受BoNT/A治疗的患者中83例(13.9%)可测出中和抗体。
- 发生NAbs的概率随单次剂量和累积剂量增加而升高,并受BoNT/A制剂影响。
- 疾病种类与治疗时长对NAbs发生无额外影响。
核心结论
- 长期重复注射BoNT/A不可避免地带来产生中和抗体的风险,但除避免加强注射和缩短注射间隔外,降低单次注射剂量可能降低NAbs诱导风险,且与BoNT/A用于何种适应证无关。
研究设计与样本
- 单中心、观察性横断面研究,纳入596例因不同适应证接受BoNT/A治疗的门诊患者,先用ELISA检测BoNT/A结合抗体,阳性样本再用小鼠半膈肌试验检测中和抗体。
主要发现
- 596例患者中83例(13.9%)可测出中和抗体。
- 发生NAbs的概率随单次剂量和累积剂量增加而升高,并受BoNT/A制剂影响;包括疾病种类和治疗时长在内的其他所有分析因素均无额外影响。
临床怎么用
- 作者认为,除避免加强注射和缩短注射间隔外,降低单次注射剂量可能降低NAbs诱导风险,且与BoNT/A所用适应证无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the prevalence of neutralizing antibodies (NAbs) against botulinum neurotoxin type A (BoNT/A) during long-term BoNT/A treatment in different neurologic indications. METHODS: In this monocentric, observational cross-sectional study, 596 outpatients treated with BoNT/A for different indications were tested for BoNT/A binding antibodies by ELISA. Positive samples were investigated for NAbs with the mouse hemidiaphragm test. The prevalence of NAbs was analyzed for different indications: facial hemispasm, blepharospasm, cervical dystonia, other dystonia, and spasticity. Besides the rate of NAb-positive patients overall and per patient subgroup, a Kaplan-Meier analysis of the probability of remaining NAb negative with duration of treatment is provided, and a stepwise binary logistic regression analysis is performed to identify factors significantly contributing to the induction of NAbs. RESULTS: Overall, 83 of 596 patients (13.9%) had measurable NAbs. The probability of developing NAbs increased with the single and cumulative dose of treatment and was influenced by the BoNT/A formulation, while all other factors analyzed, including disease entity and treatment duration, had no additional influence. CONCLUSIONS: We present the largest study to date of the prevalence of BoNT/A NAbs in a large unbiased cohort of patients including the relevant neurologic indications. Repeated injections of BoNT/A inevitably bear the risk of developing NAbs. However, in addition to avoiding booster injections and providing short intervals between injections, reducing the individual injected doses may diminish the risk of NAb induction independently of the indication for which BoNT/A is used.
引用
- Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2018. PMID: 30464031. doi:10.1212/WNL.0000000000006688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。